Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 19/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4668963 | 1.00 | DPP4 (0.78) | DPP4ALDH1A1LMNAMAPTTSHR | |
| SCHEMBL4667706 | 0.97 | DPP4 (0.73) | DPP4ALDH1A1LMNAMAPTTSHR | |
| SCHEMBL4668737 | 0.94 | DPP4 (0.71) | DPP4ALDH1A1LMNAMAPTTSHR | |
| SCHEMBL4076753 | 0.94 | DPP4 (0.71) | DPP4ALDH1A1LMNAMAPTTSHR | |
| SCHEMBL4668639 | 0.94 | DPP4 (0.71) | DPP4ALDH1A1LMNAMAPTTSHR | |
| SCHEMBL14257789 | 0.90 | DPP4 (0.74) | DPP4 | |
| SCHEMBL555434 | 0.90 | DPP4 (0.79) | DPP4ALDH1A1LMNAMAPTTSHR | |
| SCHEMBL555439 | 0.90 | DPP4 (0.79) | DPP4ALDH1A1LMNAMAPTTSHR | |
| SCHEMBL4668669 | 0.90 | DPP4 (0.79) | DPP4ALDH1A1LMNAMAPTTSHR | |
| SCHEMBL14258037 | 0.90 | DPP4 (0.79) | DPP4ALDH1A1LMNAMAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7192952-B2 | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV | NOVO NORDISK, A/S (DK) | 2007-03-20 | — | — | US | claimed |
| US-20140057901-A1 | XANTHINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2014-02-27 | — | — | US | disclosed |
| EP-2298769-B1 | Xanthin derivatives, their production and utilisation as medicine | BOEHRINGER INGELHEIM PHARMA (DE) | 2013-10-30 | — | — | EP | disclosed |
| CN-101293888-B | Xanthine derivative, production and use thereof as a medicament | BOEHRINGER INGELHEIM PHARMA | 2013-09-25 | — | — | CN | disclosed |
| US-20130165428-A1 | XANTHINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2013-06-27 | — | — | US | disclosed |
| EP-1953162-B9 | Xanthin derivatives, their production and utilisation as medicine | BOEHRINGER INGELHEIM PHARMA (DE) | 2012-10-31 | — | — | EP | disclosed |
| US-20120252783-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA & CO. KG (DE) | 2012-10-04 | — | — | US | disclosed |
| US-20120252782-A1 | Xanthine Derivatives, the Preparation Thereof and Their Use as Pharmaceutical Compositions | BOEHRINGER INGELHEIM PHARMA GMBH AND CO. KG (DE) | 2012-10-04 | — | — | US | disclosed |
| EP-1953162-B1 | Xanthin derivatives, their production and utilisation as medicine | BOEHRINGER INGELHEIM PHARMA (DE) | 2012-06-20 | — | — | EP | disclosed |
| US-20120040982-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA & CO. KG (DE) | 2012-02-16 | — | — | US | disclosed |
| US-20040077645-A1 | Dipeptidyl aminopeptidase inhibitors; diabetes mellitus, arthritis, obesity, allograft transplantation and osteoporosis treatment | BOEHRINGER INGELHEIM PHARMA GMBH & CO KG (DE) | 2004-04-22 | — | — | US | disclosed |
| WO-2004033455-A2 | HEMISUCCINATE SALTS OF HETEROCYCLIC DPP-IV INHIBITORS | NOVO NORDISK A/S (DK) | 2004-04-22 | — | — | WO | disclosed |
| EP-1404675-A1 | DPP-IV-INHIBITING PURINE DERIVATIVES FOR THE TREATMENT OF DIABETES | NOVO NORDISK A/S (DK) | 2004-04-07 | — | — | EP | disclosed |
| US-20030236272-A1 | Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states | NOVO NORDISK A/S (DK) | 2003-12-25 | — | — | US | disclosed |
| WO-2003057200-A2 | COMPOSITIONS COMPRISING INHIBITORS OF DPP-IV AND NEP ENZYMES FOR THE TREATMENT OF DIABETES | NOVO NORDISK A/S (DK) | 2003-07-17 | — | — | WO | disclosed |
| WO-2003057200-A2 | COMPOSITIONS COMPRISING INHIBITORS OF DPP-IV AND NEP ENZYMES FOR THE TREATMENT OF DIABETES | NOVO NORDISK A/S (DK) | 2003-07-17 | — | — | WO | disclosed |
| US-20030105077-A1 | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV | NOVO NORDISK A/S (DK) | 2003-06-05 | — | — | US | disclosed |
| WO-2003004496-A1 | DPP-IV-INHIBITING PURINE DERIVATIVES FOR THE TREATMENT OF DIABETES | NOVO NORDISK A/S (DK) | 2003-01-16 | — | — | WO | disclosed |
| WO-2003004496-A1 | DPP-IV-INHIBITING PURINE DERIVATIVES FOR THE TREATMENT OF DIABETES | NOVO NORDISK A/S (DK) | 2003-01-16 | — | — | WO | disclosed |
| US-20020198205-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165428-A1 | XANTHINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP4, DPP3, DPP7 | DPP4 1/4885ALDH1A1 238/4885LMNA 3445/4885 |
| US-20120252783-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | DPP4, DPP3, DPP7 | DPP4 1/4885ALDH1A1 363/4885LMNA 3410/4885 |
| US-20120252782-A1 | Xanthine Derivatives, the Preparation Thereof and Their Use as Pharmaceutical Compositions | DPP4, DPP3, DPP7 | DPP4 1/4885ALDH1A1 238/4885LMNA 3445/4885 |
| US-20140057901-A1 | XANTHINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP4, DPP3, DPP7 | DPP4 1/4885ALDH1A1 363/4885LMNA 3410/4885 |
| US-20030105077-A1 | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV | DPP4, DPP7, DPP3 | DPP4 1/4885ALDH1A1 55/4885LMNA 4341/4885 |
| US-20020198205-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | DPP4, DPP3, DPP7 | DPP4 1/4885ALDH1A1 187/4885LMNA 3797/4885 |
| US-20030236272-A1 | Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states | DPP4, GIPR, GLP1R | DPP4 1/4885ALDH1A1 2283/4885LMNA 1750/4885 |
| US-20120040982-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | DPP4, DPP3, DPP7 | DPP4 1/4885ALDH1A1 363/4885LMNA 3410/4885 |
| US-20040077645-A1 | Dipeptidyl aminopeptidase inhibitors; diabetes mellitus, arthritis, obesity, allograft transplantation and osteoporosis treatment | DPP4, DPP3, DPP7 | DPP4 1/4885ALDH1A1 178/4885LMNA 4820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.